LYFE Capital转发了
Introducing a groundbreaking achievement in healthcare investment: LYFE Capital's monumental success with ProfoundBio. Read on to discover how our global approach and strategic investments propelled ProfoundBio to a $1.8 billion acquisition by Genmab, redefining the landscape of healthcare innovation. LYFE Capital co-led the Series A round and has supported the company from A round to last round financing. We have been working with the company to transform from a local biotech to a global ADC player. We are excited for Dr. Baiteng Zhao and the Profound team on this acquisition, which will accelerate the development of ProfoundBio’s best-in-class and first-in-class ADCs to reach more patients globally. Join us in celebrating this triumph and embracing the power of global collaboration in addressing healthcare challenges worldwide!!!
News Update: Genmab to broaden and strengthen its oncology portfolio with the acquisition of ProfoundBio. Jan van de Winkel, Ph.D., President & CEO shares how the proposed acquisition of ProfoundBio, a biotechnology company focused on the development of novel antibody-drug conjugate (ADC) based therapies, will propel Genmab towards its ambitious 2030 vision to transform patients’ lives with KYSO® (Knock-your-socks-off) antibody medicines. Learn more at: https://lnkd.in/erzmStPB #News #Biotech #Oncology